EP 2 493 466 B1 relates to the antitumoral use of cabazitaxel in the treatment of prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
Brief outline of the case
The patent was originally opposed by 12 opponents under Art 100(a), (b) and (c).